MIF and metabolic dysfunction-associated steatotic liver disease: Consistent with experimental models, liver tissues from MASLD patients with hepatic metastases exhibited significant upregulation of MIF in non-tumoral parenchyma and CD44 expression in tumor cells (Fig. 6a-c).